Schreiner Group appoints Mark Wright as CFO amid strategic growth initiatives

GERMANY – Schreiner Group has appointed Mark Wright as its new Chief Financial Officer, granting him oversight of commercial activities across the company’s four global locations in Oberschleissheim, Dorfen, New York, and Shanghai.

Wright succeeds Karl Tschacha, who held the role for 15 years and will now serve as a senior management consultant, advising the advisory council and shareholders through 2026.

Wright, a graduate of Ludwig-Maximilians-Universität Munich with a real estate economist qualification from IREBS, brings 26 years of experience from Giesecke+Devrient, where he held several commercial leadership roles, including CFO of the Canadian branch and CFO of its real estate business.

“Schreiner Group has impressed me with its innovative prowess, international presence, and clear growth strategy,” Wright said.

“The CFO role combines classic financial responsibility with strategic subjects such as digitalization, making it particularly attractive.”

In his expanded role, Wright oversees finance, controlling, purchasing, IT, facility management, and commercial controlling across Schreiner’s international operations.

He identifies RFID solutions as a key growth area, highlighting a market shift from traditional labels toward data-driven, value-adding applications.

“We’re in economically turbulent times,” Wright added. “It’s vital to combine commercial stability with strategic foresight and invest systematically in forward-thinking areas.”

CEO Roland Schreiner welcomed the appointment, acknowledging Tschacha’s foundational work.

“In Mark Wright, we gain a CFO with strong international experience and a strategic perspective. He will provide critical impetus for economic control and further growth.”

The announcement comes as Schreiner Group continues to advance its product portfolio to meet evolving pharmaceutical packaging needs.

Earlier this year, the company expanded its Needle-Trap needle protection system to accommodate larger syringe formats, 2.25 ml, 3 ml, and 5 ml, responding to growing demand for biologics and biosimilars with higher fill volumes and viscous formulations.

The updated Needle-Trap retains its compact, integrated-label design, distinguishing it from conventional needle safety mechanisms and autoinjectors.

This design enables pharmaceutical manufacturers to reduce material use, lower overall system costs, and cut associated CO₂ emissions.

Importantly, the label-based safety device is compatible with standard dispensing equipment, allowing production scale-up without modifying existing lines or secondary packaging formats.

Industry analysts note that Schreiner’s dual focus on executive leadership and innovation positions the company to navigate complex market conditions while advancing sustainable, cost-efficient solutions for pharmaceutical packaging, a sector increasingly driven by digitalization and high-value injectable therapies.

Subscribe to our email newsletters that provide busy executives like you with the latest news insights and trends from Africa and the World. SUBSCRIBE HERE